| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
EDITORIAL |
1 Department of Cardiology, Royal Brompton and Harefield NHS Trust, Harefield Hospital, Middlesex, UK
2 Cardiology and Clinical Pharmacology, Experimental Medicine and Toxicology, Imperial College London, Hammersmith Campus, London, UK
Correspondence to:
Correspondence to:
H Ashrafian
Department of Cardiology, Royal Brompton and Harefield NHS Trust, Harefield Hospital, Middlesex UB9 6JH, UK; ashrafian{at}hotmail.com
R Bogle
Honorary Clinical Senior Lecturer and Acting Consultant in Medicine, Cardiology and Clinical Pharmacology, Experimental Medicine and Toxicology, Imperial College London, Hammersmith Campus, DuCane Road, London W12 0HS, UK
Accepted
8 August 2006
ABSTRACT
Yet another guideline on the prevention of infective endocarditis has been published, this time limiting prophylaxis to high-risk patients
Abbreviations: ADR, adverse drug reactions; BSAC, British Society for Antimicrobial Chemotherapy
The link between dental hygiene and infective endocarditis was made in 1909 by Horder, who observed that "infection is grafted upon a previously sclerosed endocardium...the source of the infecting agent, in most of the cases, is the mouth...".1 Accordingly, the American Heart Association, European Society of Cardiology and British Cardiac Society published guidelines on the prevention of infective endocarditis.2–4 These guidelines recommended administration of antibiotics at the time of dental treatment for all patients deemed to be at a high or moderate risk of infective endocarditis. Recently, new guidelines have been published by the Working Party of the British Society for Antimicrobial Chemotherapy (BSAC).5 The BSAC guidelines are important as their recommendations are likely to be adopted by the British National Formulary (BNF) and will be influential in medico-legal disputes. In contrast with previous guidelines, BSAC recommend dental prophylaxis in only three circumstances: previous infective endocarditis, prosthetic valves, and surgically constructed pulmonary shunts or conduits. This radical step to limit prophylaxis to high-risk patients has been welcomed by the dental community who laud the guidelines as "a victory for science and common sense."6
RATIONALE FOR PROPHYLAXIS
The enduring rationale for prophylaxis has been to identify at-risk patients and protect them during presumptive episodes of increased risk. It is established that dental treatment causes bacteraemia, as does teeth brushing, and also that bacteraemia is associated with seeding of abnormal valves in experimental animal studies.7 Traditional guidelines advocating broader prophylaxis were based on extensive animal and human data showing the capacity of dental interventions to induce bacteraemia and that of the antibiotic sulphathiazole to considerably reduce bacteraemia.8 Although reducing bacteraemia in higher risk populations may be desirable, the scientific emphasis is moving away from procedure-related bacteraemia towards cumulative bacteraemia.5 In actuarial terms, the procedure-related bacteraemia, from activities such as brushing, is estimated to be 6 million times higher than that occurring from a single tooth extraction. Although this newer stance is intuitive and influential, it is noteworthy that dental extraction, albeit in children, delivers a larger more prolonged bacteraemia than less vigorous cleaning work. If the risk of infective endocarditis is not just dependant on low-level cumulative exposure but is also influenced by peak sustained intravascular bacterial dynamics, investigators cautiously conclude "prophylaxis [may be] effective and desirable."9
The evidence base to which we normally strongly adhere is in this context equally confusing. Anecdotally in England and Wales about 1.35 million dental procedures are carried out on "at-risk patients" (mainly mitral valve prolapse) every year and only about 50% of these receive appropriate prophylaxis.10 Therefore a large number of "at-risk patients" undergo procedures without prophylaxis. Contrast this with only 1500 annual cases of infective endocarditis, most of which are thought to be of non-dental origin. This suggests that for the bulk of patients with conditions such as mitral valve prolapse, prophylaxis is not necessary. Although the literature contains observational studies suggesting the failure of prophylaxis,11–14 even these studies indicate a trend towards infective endocarditis in procedures such as extraction and significant dento-gingival manipulation.12 Conversely, while there is also evidence that dental work, especially extractions, increase the risk of infective endocarditis fivefold and prophylaxis prevents 70% of these cases, it is noted that most cases need prophylaxis to prevent a small number of infective endocarditis episodes.15 This equipoise has been best articulated by the Cochrane Collaboration who concluded "There is no evidence about whether penicillin prophylaxis is effective or ineffective against infective endocarditis in people at risk who are about to undergo an invasive dental procedure. There is a lack of evidence to support published guidelines in this area and it is not clear whether the potential harms and costs of penicillin administration outweigh any beneficial effect."16
RANDOMISED CONTROLLED TRIAL
To settle this controversy, many, including the Working Party of the BSAC, have called for a randomised controlled trial to evaluate the risk or benefit of antibiotics. Such a mega-trial would require >6000 at-risk participants and would encounter strong ethical concerns as well as being arduous and expensive.1 However, there may be another approach; there is an analogy between procedural infective endocarditis and adverse drug reactions (ADR). Both occur rarely, and a randomised controlled trial, unless massive, would be inadequately powered to omit type II errors; both have an unknown and probably heterogeneous temporal association with the inciting event and both affect people who are genetically or structurally predisposed. Unlike ADR, where fiscal incentives and governmental regulation have stimulated pharmacoepidemiology, powered by automated systematic databases, infective endocarditis prophylaxis is hampered by small studies that confuse rather than illuminate. Even the International Collaboration on Endocarditis, boasting a database of >2200 patients with infective endocarditis, is probably underpowered to settle this controversy. To settle lingering doubts regarding procedural infective endocarditis, a systematic (inter)national ADR-like reporting system is required which needs to be established between the dental and cardiology communities.
Ultimately, one of the compelling themes of the BSAC guidelines is that prophylaxis is not risk free and is a matter of concern when prescribing treatment to prevent rather than treat disease on the basis of an assessment of actuarial risk or scientific rationale. The pencillins are allergenic and exposure is one of the most common causes of anaphylactic reactions; 1–10% of patients report a penicillin allergy and the chance of a penicillin reaction is about 5% for high doses of oral amoxicillin. It has been calculated that in such a large unselected population patient receiving amoxicillin prophylaxis, the risk of death from anaphylactic reactions is five times grater than from contracting infective endocarditis. In addition, minor adverse reactions, unfavourable cost-effectiveness and increasing antibiotic resistance are also reasons cited to avoid antibiotic prophylaxis.
CLINICAL DISCRETION REQUIRED
The BSAC guidelines are probably an adroit step in the right direction. However, for the overall cohort of patients, prophylaxis may indeed not be appropriate and may indeed be potentially harmful; there are certainly patients with intermediate risks that cohort studies fail to represent. After all, the absence of evidence does not reflect evidence of absence and in such a balanced clinical situation, clinical discretion is of paramount importance.16 In the context of this equipoise, such legally compelling guidelines might have done well to have taken a more flexible approach and consulted a broader parish of practitioners that primarily care for and counsel potential and actual patients with infective endocarditis. What then for the cardiologist, dentist and patient? The next few months are likely to be difficult for all. Cardiologists may feel uncomfortable about changing their recommendations for moderate-risk patients in line with the BSAC guidelines, while their own professional societies’ published guidelines continue to recommend antibiotics for this group. This is especially true if they perceive the BSAC guidelines to be merely a reassessment of that which was already known. A revised statement of guidance from the British Cardiovascular Society has been helpful and NICE has agreed to undertake an urgent review of antibiotic prophylaxis.18 For the dentist the position is also difficult; patients will often have a letter recommending prophylaxis in their dental records or will carry an infective endocarditis dental warning card, whereas these new BSAC guidelines recommend antibiotic prophylaxis in much more limited circumstances. The dentist is an independent clinical practitioner with legal responsibility for prescribing the antibiotics; they cannot simply follow the cardiologist’s recommendations blindly. The Chief Dental Officer has written to all dentists with the recommendation that they should adhere to the guidance published in the BNF. If a patient were to have an anaphylactic reaction, the dentist would not be able to adopt the defence that "the cardiologist made me do it". Also for the patient this is a time of uncertainty—particularly for those who have had antibiotic prophylaxis for many years and are now told that it is no longer necessary. Therefore it is essential that patients are adequately counselled on the benefits of good dental hygiene and a discussion is undertaken and documented on the risks or benefits of antibiotic prophylaxis—if that is done hasn’t good practice been satisfied?
FOOTNOTES
Published Online First 16 August 2006
Competing interests: None declared.
REFERENCES
Related Articles
This article has been cited by other articles:
|
|
 |
|
  B D Prendergast, J L Harrison, and C K Naber Commentary on endocarditis prophylaxis: a quaint custom or medical necessity? Heart, July 1, 2008; 94(7): 931 - 934. [Full Text] [PDF]
|
|
|
|
|
|
X. Duval, C. Leport, and N. Danchin The new American Heart Association guidelines on the prevention of infective endocarditis: culmination of a long process of thought Heart, June 1, 2008; 94(6): 715 - 716. [Full Text] [PDF]
|
|
|
|
 |
|
 W. Wilson, K. A. Taubert, M. Gewitz, P. B. Lockhart, L. M. Baddour, M. Levison, A. Bolger, C. H. Cabell, M. Takahashi, R. S. Baltimore, et al. Prevention of infective endocarditis: Guidelines from the American Heart Association: A guideline from the American Heart Association Rheumatic Fever, Endocarditis and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group J Am Dent Assoc, January 1, 2008; 139(suppl_1): 3S - 24S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Wilson, K. A. Taubert, M. Gewitz, P. B. Lockhart, L. M. Baddour, M. Levison, A. Bolger, C. H. Cabell, M. Takahashi, R. S. Baltimore, et al. Prevention of Infective Endocarditis: Guidelines From the American Heart Association: A Guideline From the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group Circulation, October 9, 2007; 116(15): 1736 - 1754. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Wilson, K. A. Taubert, M. Gewitz, P. B. Lockhart, L. M. Baddour, M. Levison, A. Bolger, C. H. Cabell, M. Takahashi, R. S. Baltimore, et al. Prevention of infective endocarditis: Guidelines from the American Heart Association: A guideline from the American Heart Association Rheumatic Fever, Endocarditis and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group J Am Dent Assoc, June 1, 2007; 138(6): 739 - 760. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Burch The correspondence column is back Heart, June 1, 2007; 93(6): 658 - 658. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A C Chalmers and D M Pullan Antimicrobial prophylaxis for endocarditis: Letter to the Editor (1) Heart, June 1, 2007; 93(6): 753 - 753. [Full Text] [PDF]
|
|
|
|
|
|
D. R Ramsdale and N. D Palmer Antimicrobial prophylaxis for endocarditis: Letter to the Editor (2) Heart, June 1, 2007; 93(6): 753 - 753. [Full Text] [PDF]
|
|
|
|
|
|
R. G Bogle and H. Ashrafian The authors reply Heart, June 1, 2007; 93(6): 753 - 754. [Full Text] [PDF]
|
|
Read all eLetters
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
